Simulations Plus

Simulations Plus is the only non-European company invited to consortium

Pharmaceutical Software and Services Revenues Increase 14.9% for Record 4th Quarter, up 8.1% for the Record Fiscal Year

Company declares cash dividend of $0.05 per share

3rd quarter sales increase 5.0% to $2.77 million; 9 months net income up 5.9% to $2.68 million

Conference Call to Be on Thursday, July 12, at 4:15 PM ET

Ms. Anu Sharma Joins the Company as Senior Sales and Marketing Manager, focusing on Cheminformatics Products

Major Pharmaceutical Company to Fund Transdermal and Subcutaneous Drug Absorption Model in GastroPlus

Major Pharmaceutical Company to Fund Enhanced Oral Cavity Model in GastroPlus™

Net sales increase 4.9% to new 3rd quarter record of $2.77 million

Molecule Design Tools Used in Company’s Malaria Drug Design Project Released

Major New Upgrade Increases Power of Its Best-in-Class Software

Integrates MedChem Designer™ Molecule Drawing, Features Graphical User Interface Improvements and Further Enhanced Molecular Property Predictions

Company declares cash dividend of $0.05 per share

Activity Seen Against Both Drug-Sensitive and Drug-Resistant Strains

Net sales increase 6.4% to record for any quarter of $2.789 million; first half net income up 22.7% to $1.810 million

Conference Call to Be on Tuesday, April 10, at 4:15 PM ET

New Molecule Has Excellent Activity Against Malaria Parasite

Company Now Owns IP in ADMET Predictor™ Enslein Metabolism Module